Italy · Delayed Price · Currency is EUR Philogen Company Description
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases in Switzerland and the European Union.
The company develops Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF, which is in Phase III trial for the intralesional treatment of locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF in Phase III trial to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in Phase II trial for the treatment of non-small cell lung cancer.
It is also developing Dekavil (F8IL10), an anti-inflammatory product in Phase II trial for the treatment of chronic inflammatory disorders; Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12, which is in Phase I trial to treat advanced solid tumors; OncoFAP radio conjugates, a small molecule radiotracer with ultra high affinity for fibroblast activation protein in Phase I trial for diagnostic and therapeutic applications of metastatic solid tumors; OncoACP3, a small molecule radiotracer with ultra high-affinity for acid phosphatase 3 in Phase I trial for diagnostic and therapeutic applications for prostate cancer; OncoCAIX, a small molecule radiotracer in Phase 1 trial for the detection of Carbonic Anhydrase IX (CAIX) expressed in renal cell carcinoma and other hypoxic tumors; and OncoFAP-GlyPro-MMAE, a small molecule drug conjugate with ultra-high affinity for fibroblast activation protein in preclinical trial for the treatment of solid tumors.
Philogen S.p.A. was founded in 1996 and is headquartered in Siena, Italy.
| Country | Italy |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 183 |
| CEO | Dario Neri |
Contact Details
Address: Piazza La Lizza #7 Siena, 53100 Italy | |
| Phone | 39 05 7717816 |
| Website | philogen.com |
Stock Details
| Ticker Symbol | PHIL |
| Exchange | Borsa Italiana |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | IT0005373789 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Prof. Dario Neri Ph.D. | Co-Founder, Chief Executive Officer , MD, CSO, President of the Scientific Advisory Board and Director |
| Dr. Duccio Neri | Co-Founder and Executive Chairman |
| Dr. Giovanni Neri | Co-Founder, MD, Head of IP and Licensing and Executive Director |
| Laura Baldi | Chief Financial Officer |
| Dr. Alfredo Covelli M.D. | Chief Medical Officer |
| Dr. Katia Lorizzo | Deputy CMO and Head of Clinical Operations |